Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Pharmacogenomics in Practice
Wang, Liewei , Weinshilboum, Richard M. , Weinshilboum, Richard, Weinshilboum, Richard M.

Mayo Clinic

Clinical Pharmacology & Therapeutics | September 9, 2019 | Volume: 106 | Issue: 5 | Pages: 936-938

10.1002/cpt.1600 | PMID 31498426 Get It

Patch Testing with a Large Series of Metal Allergens: Findings from More Than 1,000 Patients in One Decade at Mayo Clinic
Davis, Mark D.P. , Wang, Michael Z. , Yiannias, James A. , Keeling, James H., Connolly, Suzanne M., Richardson, Donna M., Farmer, Sara A.

Mayo Clinic

Dermatitis® | September 6, 2019 | Volume: 22 | Issue: 5 | Pages: 256-271

10.2310/6620.2011.11035 | PMID 22652903 Get It

Background: The standard allergen series used in patch testing contains metals that most commonly cause allergic contact dermatitis, but testing with additional metal allergens is warranted for select patients. Objective: To report our experience with patch testing of metals. Methods: We retrospectively analyzed outcomes of 1,112 patients suspected of having metal allergies. Patients were seen from January 1, 2000, through December 31, 2009. Patch testing was performed with 42 metal preparations (6 in the standard series, 36 in the metal series). Results: Patch testing most commonly was performed for patients with oral disease (almost half the patients), hand dermatitis, generalized dermatitis, and dermatitis affecting the lips, legs, arms, trunk, or face. At least one positive reaction was reported for 633 patients (57%). Metals with the highest allergic patch-test reaction rates were nickel, gold, manganese, palladium, cobalt, Ticonium, mercury, beryllium, chromium, and silver. Metals causing no allergic patch-test reactions were titanium, Vitallium, and aluminum powder. Metals with extremely low rates of allergic patch-test reactions included zinc, ferric chloride, and tin. Reaction rates varied depending on metal salt, concentration, and timing of readings. Conclusion: Many metals not in the standard series were associated with allergic patch-test reactions. The many questions raised by these findings, concerning patch testing with individual metals, will be the subject of future studies.
Patch-Testing with Hairdressing Chemicals
Wang, Michael Z. , Farmer, Sara A., Richardson, Donna M., Davis, Mark D.P.

Mayo Clinic

Dermatitis® | September 6, 2019 | Volume: 22 | Issue: 1 | Pages: 16-26

10.2310/6620.2010.10061 Get It

Background: Hairdressing chemicals may be associated with allergic contact dermatitis. Objective: To review our experience of patch-testing with hairdressing chemicals. Methods: We reviewed results from patients who underwent patch testing with our standard allergen series (including 15 hairdressing chemicals) and a supplementary “hairdresser series” (18 additional hairdressing chemicals) at Mayo Clinic (Rochester, MN; Scottsdale, AZ; and Jacksonville, FL) from January 1, 2000, through December 31, 2008. Results: Two hundred ten patients (mean age, 53.8 years [SD, 16.9 yr]; female, 94.8%) were patch-tested. The most common sites of dermatitis were the scalp, face, and hands. Patients had widely varying occupations. The most common occupations were cosmetologist (10.5%), housewife (9.5%), and beautician (5.2%); 14.3% were retired. The hairdresser series detected 13 additional patients with allergies (6.4%; 204 patients tested with both series) who would not have been detected with the standard allergen series alone. The highest allergic patch-test rates in the supplemental hairdresser series were with ammonium persulfate (14.4%), 4-aminoazobenzene (13.4%), and pyrogallol (9.1%). Conclusions: Patch-testing with hairdressing-specific chemicals (standard series plus supplemental hairdresser series) was appropriate for numerous clinical situations and was not limited to patients in hair care occupations. The supplemental hairdresser series helped identify more patients than would have been identified with the standard series alone.
Haploinsufficiency of mechanistic target of rapamycin ameliorates bag3 cardiomyopathy in adult zebrafish
Ding, Yonghe , Dvornikov, Alexey V. , Ma, Xiao , Wang, Yong , Lowerison, Matthew R. , Packard, René R. Sevag , Wang, Lei , Zhang, Yuji , Lowerison, Matthew, Lin, Xueying , Lowerison, Matthew , Ding, Yonghe , Zhang, Hong , Chen, Jun , Hsiai, Tzung K. , Xu, Xiaolei , Packard, Rene R S

Mayo Clinic

Disease Models & Mechanisms | September 6, 2019 | Volume: 12 | Issue: 10 | Pages: No page available

10.1242/dmm.040154 | PMID 31492659 Get It

ABSTRACT The adult zebrafish is an emerging vertebrate model for studying human cardiomyopathies; however, whether the simple zebrafish heart can model different subtypes of cardiomyopathies, such as dilated cardiomyopathy (DCM), remains elusive. Here, we generated and characterized an inherited DCM model in adult zebrafish and used this model to search for therapeutic strategies. We employed transcription activator-like effector nuclease (TALEN) genome editing technology to generate frame-shift mutants for the zebrafish ortholog of human BCL2-associated athanogene 3 (BAG3), an established DCM-causative gene. As in mammals, the zebrafish bag3 homozygous mutant (bag3e2/e2) exhibited aberrant proteostasis, as indicated by impaired autophagy flux and elevated ubiquitinated protein aggregation. Through comprehensive phenotyping analysis of the mutant, we identified phenotypic traits that resembled DCM phenotypes in mammals, including cardiac chamber enlargement, reduced ejection fraction characterized by increased end-systolic volume/body weight (ESV/BW), and reduced contractile myofibril activation kinetics. Nonbiased transcriptome analysis identified the hyperactivation of the mechanistic target of rapamycin (mTOR) signaling in bag3e2/e2 mutant hearts. Further genetic studies showed that mtorxu015/+, an mTOR haploinsufficiency mutant, repaired abnormal proteostasis, improved cardiac function and rescued the survival of the bag3e2/e2 mutant. This study established the bag3e2/e2 mutant as a DCM model in adult zebrafish and suggested mtor as a candidate therapeutic target gene for BAG3 cardiomyopathy.
Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma
Yarchoan, Mark , Agarwal, Parul , Rao, Shuyun , Dawson, Laura A. , Llovet, Josep M. , Groopman, John D. , El‐Serag, Hashem B. , Monga, Satdarshan P. , Wang, Xin Wei , Roberts, Lewis R. , Gunaratne, Preethi H. , Tsung, Allan , Brown, Kimberly , Lawrence, Theodore S. , Kim, Amy K. , Rabiee, Atoosa , Resar, Linda , Meyer, Jeffrey , He, Aiwu Ruth , Ghoshal, Kalpana , Ryan, Patrick , Jaffee, Elizabeth M. , Guha, Chandan , Mishra, Lopa , Coleman, C. Norman, Ahmed, Mansoor M. , Groopman, John D , El-Serag, Hashem B , Roberts, Lewis R , Wei Wang, Xin , Lawrence, Theodore S , Yarchoan, Mark , Monga, Satdarshan , Villanueva, Augusto , Karasic, Thomas Benjamin , Finn, Richard S. , Karin, Michael , Schwartz, Robert E. , Tanabe, Kenneth K. , Salem, Riad , Singal, Amit G. , Hoshida, Yujin

Mayo Clinic

Cancer Research | September 3, 2019 | Volume: 79 | Issue: 17 | Pages: 4326-4330

10.1158/0008-5472.can-19-0803 | PMID 31481419 Get It

Abstract Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2–5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.
Urinary extracellular vesicle-associated MCP-1 and NGAL derived from specific nephron segments differ between calcium oxalate stone formers and controls
Chirackal, Robin S., Jayachandran, Muthuvel , Wang, Xiangling , Edeh, Samuel, Haskic, Zejfa , Perinpam, Majuran, Halling, Timothy, Mehta, Ramila A. , Rivera, Marcelino , Halling, Timothy M, Mehta, Ramila, Rivera, Marcelino E, Lieske, John C.

Mayo Clinic

American Journal of Physiology-Renal Physiology | August 28, 2019 | Volume: 317 | Issue: 6 | Pages: F1475-F1482

10.1152/ajprenal.00515.2018 | PMID 31461349 Get It

Randall’s plaque (RP; subepithelial calcification) appears to be an important precursor of kidney stone disease. However, RP cannot be noninvasively detected. The present study investigated candidate biomarkers associated with extracellular vesicles (EVs) in the urine of calcium stone formers (CSFs) with low (<5% papillary surface area) and high (≥5% papillary surface area) percentages of RP and a group of nonstone formers. RPs were quantitated via videotaping and image processing in consecutive CSFs undergoing percutaneous surgery for stone removal. Urinary EVs derived from cells of different nephron segments of CSFs ( n = 64) and nonstone formers ( n = 40) were quantified in biobanked cell-free urine by standardized and validated digital flow cytometer using fluorophore-conjugated antibodies. Overall, the number of EVs carrying surface monocyte chemoattractant protein (MCP)-1 and neutrophil gelatinase-associated lipocalin (NGAL) were significantly lower in CSFs compared with nonstone former controls ( P < 0.05) but did not differ statistically between CSFs with low and high RPs. The number of EVs associated with osteopontin did not differ between any groups. Thus, EVs carrying MCP-1 and NGAL may directly or indirectly contribute to stone pathogenesis as evidenced by the lower of these populations of EVs in stone formers compared with nonstone formers. Validation of EV-associated MCP-1 and NGAL as noninvasive biomarkers of kidney stone pathogenesis in larger populations is warranted.
Diffuse Alveolar Hemorrhage in Stem Cell Transplant Recipients
Zhang, Z., Wang, Chenxiao , Yadav, H., Niven, Alexander S.

Mayo Clinic

A44. CRITICAL CARE: ONE THOUSAND AND ONE NIGHTS - NON-PULMONARY CRITICAL CARE | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A1673-A1673

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1673 Get It

Lung Ultrasound to Detect Allograft Dysfunction in Lung Transplant Recipients
Narula, Tathagat , Sahoo, Debasis , Krishnan, Sudhir , Han, Xiaozhen , Wang, X. , Budev, Marie, Banga, Amit , Mehta, Atul C. , Moghekar, Abhay

Mayo Clinic

B31. LUNG TRANSPLANTATION: CLINICAL AND MECHANISTIC STUDIES | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A2886-A2886

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2886 Get It

Genome‐Wide Meta‐Analysis of Blood Pressure Response to β 1 ‐Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies)
Hiltunen, Timo P. , McDonough, Caitrin W. , Rouby, Nihal El , Salvi, Erika , Wang, Zhiying , Garofalidou, Tatiana, Fyhrquist, F, Kontula, Kimmo , Glorioso, Valeria, Zaninello, Roberta, Glorioso, Nicola, Pepine, Carl J. , Munroe, Patricia B. , Turner, Stephan T., Chapman, Arlene B. , Boerwinkle, Eric , Johnson, Julie A. , Munroe, Patricia B , Singh, Sonal , Warren, Helen R. , Chapman, Arlene B. , Gong, Yan , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Journal of the American Heart Association | August 19, 2019 | Volume: 8 | Issue: 16 | Pages: No page available

10.1161/jaha.119.013115 | PMID 31423876 Get It

Background There exists a wide interindividual variability in blood pressure ( BP ) response to β 1 ‐blockers. To identify the genetic determinants of this variability, we performed a pharmacogenomic genome‐wide meta‐analysis of genetic variants influencing β 1 ‐blocker BP response. Methods and Results Genome‐wide association analysis for systolic BP and diastolic BP response to β 1 ‐blockers from 5 randomized clinical trials consisting of 1254 patients with hypertension of European ancestry were combined in meta‐analysis and single nucleotide polymorphisms (SNPs) with P <10 −4 were tested for replication in 2 independent randomized clinical trials of β 1 ‐blocker–treated patients of European ancestry (n=1552). Regions harboring the replicated SNP s were validated in a β 1 ‐blocker–treated black cohort from 2 randomized clinical trials (n=315). A missense SNP rs28404156 in BST 1 was associated with systolic BP response to β 1 ‐blockers in the discovery meta‐analysis ( P =9.33×10 −5 , β=−3.21 mm Hg) and replicated at Bonferroni significance ( P =1.85×10 −4 , β=−4.86 mm Hg) in the replication meta‐analysis with combined meta‐analysis approaching genome‐wide significance ( P =2.18×10 −7 ). This SNP in BST 1 is in linkage disequilibrium with several SNP s with putative regulatory functions in nearby genes, including CD 38 , FBXL 5 , and FGFBP 1 , all of which have been implicated in BP regulation. SNP s in this genetic region were also associated with BP response in the black cohort. Conclusions Data from randomized clinical trials of 8 European ancestry and 2 black cohorts support the assumption that BST 1 containing locus on chromosome 4 is associated with β 1 ‐blocker BP response. Given the previous associations of this region with BP , this is a strong candidate region for future functional studies and potential use in precision medicine approaches for BP management and risk prediction.
Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism
Lindström, Sara , Wang, Lu , Smith, Erin N. , Gordon, William, Vlieg, Astrid van Hylckama , Andrade, Mariza de , Brody, Jennifer A. , Pattee, Jack , Haessler, Jeffrey, Brumpton, Ben , Suchon, Pierre , Chen, Ming‐Huei , Germain, Marine , Wiggins, Kerri L. , Brækkan, Sigrid K. , Armasu, Sebastian M. , Jackson, Rebecca D., Giulianini, Franco, Puurunen, Marja , Ibrahim, Manal , Heckbert, Susan R. , Natarajan, Pradeep , Klarin, Derek , Program, The Million Veteran, Vries, Paul S. de , Sabater‐Lleal, Maria , Group, The CHARGE Hemostasis Working, Bammler, Theo K. , Frazer, Kelly A. , McCauley, Bryan M. , Pankow, James S. , Reiner, Alex P. , Gabrielsen, Maiken E. , Kim, Jihye , McKnight, Barbara, Hansen, J.-B., Heit, John A. , Tang, Weihong , Morange, Pierre‐Emmanuel , Johnson, Andrew D. , Kabrhel, Christopher , Trégouët, David‐Alexandre , Smith, Nicholas L. , Assimes, Themistocles L. , Ballantyne, Christie M. , Hansen, John‐Bjarne , Frazer, Kelly A , de Andrade, Mariza , Assimes, Themistocles L , Wiggins, Kerri L , Ballantyne, Christie M , Natarajan, Pradeep , Braekkan, Sigrid K , Germain, Marine , Brumpton, Ben , Sabater-Lleal, Maria , Pankow, James S , Tang, Weihong , Brody, Jennifer A , Chasman, Daniel I. , Turman, Constance , MacDonald, James W. , Pankratz, Nathan , Nielsen, Jonas Bille , Damrauer, Scott M , Program, The Million Veteran, Huffman, Jennifer E. , Group, The CHARGE Hemostasis Working, Taylor, Kent D. , Deleuze, Jean‐François , O'Donnell, Chris J., Kraft, Peter , Rosendaal, Frits R , Psaty, Bruce M. , Kooperberg, Charles , Hveem, Kristian , Ridker, Paul M.

Mayo Clinic

Blood | August 16, 2019 | Volume: 134 | Issue: 19 | Pages: 1645-1657

10.1182/blood.2019000435 | PMID 31420334 Get It

In this work related to familial aggregation of familial venous thromboembolism, the investigators report genomic and transcriptomic association of 16 novel susceptibility loci for venous thromboembolism.